TP53 and neoplasm: In addition, complementation of these studies with direct TP53 sequencing of ESFT material would identify either patients with wild-type p53 tumours most likely to benefit from p53-based therapies or the less frequent “high risk” population of ESFTs containing point mutations in the TP53 gene.